Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (201-210 of 259) with videos related to

Pageof 26
Sort By:
Breast (Edinburgh, Scotland)|September 25, 2013
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialHatem A Azim, Francoise Rothé, Claudia Monica Aura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 15, 2024
A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy surveyCarmela Caballero, Dara J Lundon, Mariela Vasileva-Slaveva, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2024
Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in BelgiumRoos Leroy, Geert Silversmit, Jolyce Bourgeois, et al.
Breast (Edinburgh, Scotland)|September 7, 2013
Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statementPatricia A Ganz, Cheng Har Yip, Julie R Gralow, et al.
Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
Pageof 26

Showing results (201-210 of 259) with videos related to

Sort By:
Pageof 26
Breast (Edinburgh, Scotland)|September 25, 2013
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialHatem A Azim, Francoise Rothé, Claudia Monica Aura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 15, 2024
A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy surveyCarmela Caballero, Dara J Lundon, Mariela Vasileva-Slaveva, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2024
Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in BelgiumRoos Leroy, Geert Silversmit, Jolyce Bourgeois, et al.
Breast (Edinburgh, Scotland)|September 7, 2013
Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statementPatricia A Ganz, Cheng Har Yip, Julie R Gralow, et al.
Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
Pageof 26